Arbutus Biopharma Corporation (ABUS) Stock Forecast
ABUS analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $5.40 average of analyst targets
- Upside to target
- +27.9% from the latest close
- Next earnings
- November 12, 2026
- 52-week range
- $3.67 – $5.22
ABUS analyst ratings
1 analystsNumber of analysts at each rating.
ABUS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ABUS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.03 | −$0.03 | −$0.03 | −$0.06 | +50.0% | 1 |
| Current fiscal year (2026) | $1.03 | $1.03 | $1.03 | −$0.23 | +540.4% | 1 |
| Next fiscal year (2027) | −$0.11 | −$0.11 | −$0.11 | $1.03 | −110.8% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ABUS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.4M | $1.4M | $1.4M | +87.4% | 1 |
| Current fiscal year (2026) | $252.8M | $252.8M | $252.8M | +1,208.8% | 1 |
| Next fiscal year (2027) | $5.7M | $5.7M | $5.7M | −97.8% | 1 |
ABUS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ABUS revenue: reported and forecast
ABUS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.03 | −$0.03 | −$0.03 | −$0.03 | −$0.03 | +3.7% | 0 up · 1 down |
| Current fiscal year (2026) | $1.03 | $1.03 | $1.03 | $1.03 | $1.03 | −0.3% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.12 | −$0.12 | −$0.12 | −$0.12 | −$0.11 | −10.5% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ABUS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ABUS beat in 7 of 12.
What analysts expect from ABUS
1 analysts cover Arbutus Biopharma; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.40, 27.9% above the latest close of $4.22. Analysts expect earnings of $1.03 per share for 2026, +540.4% from a year earlier. For 2027 the average estimate is −$0.11 per share on revenue of $5.7 million. Arbutus Biopharma beat the EPS estimate in 7 of the last 12 quarters.
Related: ABUS income statement, ABUS key metrics, ABUS chart. See the ABUS stock overview for the latest quote and news.
ABUS forecast FAQ
What is Arbutus Biopharma's price target?
The average analyst price target for Arbutus Biopharma is $5.40, 27.9% above the latest close of $4.22.
Is Arbutus Biopharma a buy, hold or sell?
Of 1 analysts covering Arbutus Biopharma, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Arbutus Biopharma's EPS forecast?
Analysts forecast $1.03 per share for 2026 (range $1.03 to $1.03); for 2027 the estimate is −$0.11.
What is Arbutus Biopharma's revenue forecast?
The average revenue estimate for 2026 is $252.8 million, growth of 1,208.8%; for 2027 it is $5.7 million.
When does Arbutus Biopharma report earnings?
Arbutus Biopharma is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
Does Arbutus Biopharma usually beat earnings estimates?
Arbutus Biopharma reported EPS at or above the analyst estimate in 7 of the last 12 quarters.